Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M—which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.